Clinical trial
Sapphire 3 - A Prospective, Open Label, Multi-center, Single Arm, Observational Study Designed to Evaluate the Acute Safety and Device Performance of the Sapphire 3 0.85-1.25 mm Coronary Dilatation Catheter in Predilatation of Chronic Total Occlusion (CTO) Lesions During Percutaneous Coronary Intervention.
NCT06358508 is registered in ClinicalTrials.gov with OrbusNeich as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Sapphire 3 - A Prospective, Open Label, Multi-center, Single Arm, Observational Study Designed to Evaluate the Acute Safety and Device Performance of the Sapphire 3 0.85-1.25 mm Coronary Dilatation Catheter in Predilatation of Chronic Total Occlusion (CTO) Lesions During Percutaneous Coronary Intervention.
- Lead sponsor
- OrbusNeich
- Phase
- Not applicable
- Overall status
- Completed
- Start date
- November 6, 2024
- Completion date
- October 21, 2025
- Enrollment
- 170 (actual)
- Sites
- 14
Conditions
As the registry lists them; a condition with its own page is linked.
arteriosclerosis, cardiovascular diseases, chronic total occlusion, chronic total occlusion of coronary artery, coronary artery disease, coronary disease, heart diseases, myocardial ischemia